Marks Group Wealth Management Inc Has $496,000 Holdings in Boston Scientific Corporation $BSX

Marks Group Wealth Management Inc trimmed its position in Boston Scientific Corporation (NYSE:BSX) by 5.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 4,615 shares of the medical equipment provider’s stock after selling 268 shares during the period. Marks Group Wealth Management Inc’s holdings in Boston Scientific were worth $496,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. HM Payson & Co. boosted its stake in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider’s stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. IVC Wealth Advisors LLC raised its holdings in Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after buying an additional 102 shares during the last quarter. Park Square Financial Group LLC boosted its position in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC grew its holdings in Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 103 shares during the last quarter. Finally, Rise Advisors LLC increased its position in Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 103 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $17,972,457 over the last three months. Company insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on BSX shares. Barclays boosted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Saturday, September 27th. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. UBS Group upped their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Finally, Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $120.79.

Boston Scientific Stock Performance

NYSE BSX opened at $96.73 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a fifty day simple moving average of $102.75 and a 200 day simple moving average of $102.04. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a market cap of $143.33 billion, a P/E ratio of 57.58, a PEG ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.